Question 1

What is Thymmune Therapeutics?

Accepted Answer

Thymmune Therapeutics is a Entity.

Question 2

How often does Thymmune Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Thymmune Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Jul 02, 2026.

Question 4

When was Thymmune Therapeutics last mentioned in news?

Accepted Answer

Last active on Jul 02, 2026.

Question 5

What is Thymmune Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Thymmune Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Thymmune Therapeutics?

Accepted Answer

United Therapeutics acquires Thymmune Therapeutics (Jul 02, 2026, 7 articles).

Question 8

How did the "United Therapeutics acquires Thymmune Therapeutics" event impact Thymmune Therapeutics?

Accepted Answer

Thymmune Therapeutics, Inc. was acquired by United Therapeutics for $140 million in cash, plus potential earn-out payments. This acquisition provides Thymmune Therapeutics, Inc. with resources to advance its preclinical stage regenerative thymic cell therapies, particularly THY-100, for various immune-mediated diseases.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.